235 related articles for article (PubMed ID: 26982812)
21. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
[TBL] [Abstract][Full Text] [Related]
22. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
Moons T; Claes S; Martens GJ; Peuskens J; Van Loo KM; Van Schijndel JE; De Hert M; van Winkel R
Schizophr Res; 2011 Feb; 125(2-3):187-93. PubMed ID: 21050724
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics.
Vassas TJ; Burghardt KJ; Ellingrod VL
Pharmacogenomics; 2014 Jan; 15(1):61-7. PubMed ID: 24329191
[TBL] [Abstract][Full Text] [Related]
24. Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia.
Hattori S; Suda A; Kishida I; Miyauchi M; Shiraishi Y; Fujibayashi M; Tsujita N; Ishii C; Ishii N; Moritani T; Taguri M; Hirayasu Y
BMC Psychiatry; 2018 Jul; 18(1):231. PubMed ID: 30016952
[TBL] [Abstract][Full Text] [Related]
25. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.
Ellingrod VL; Miller DD; Taylor SF; Moline J; Holman T; Kerr J
Schizophr Res; 2008 Jan; 98(1-3):47-54. PubMed ID: 17976958
[TBL] [Abstract][Full Text] [Related]
26. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.
Hong CJ; Liou YJ; Bai YM; Chen TT; Wang YC; Tsai SJ
Pharmacogenet Genomics; 2010 Jun; 20(6):359-66. PubMed ID: 20375926
[TBL] [Abstract][Full Text] [Related]
27. Lack of association between SREBF-1c gene polymorphisms and risk of non-alcoholic fatty liver disease in a Chinese Han population.
Peng XE; Chen FL; Liu W; Hu Z; Lin X
Sci Rep; 2016 Aug; 6():32110. PubMed ID: 27572914
[TBL] [Abstract][Full Text] [Related]
28. Second generation antipsychotic-induced mitochondrial alterations: Implications for increased risk of metabolic syndrome in patients with schizophrenia.
Scaini G; Quevedo J; Velligan D; Roberts DL; Raventos H; Walss-Bass C
Eur Neuropsychopharmacol; 2018 Mar; 28(3):369-380. PubMed ID: 29449054
[TBL] [Abstract][Full Text] [Related]
29. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
30. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
31. A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia.
Gonçalves VF; Zai CC; Tiwari AK; Brandl EJ; Derkach A; Meltzer HY; Lieberman JA; Müller DJ; Sun L; Kennedy JL
Neuropsychopharmacology; 2014 May; 39(6):1347-54. PubMed ID: 24196945
[TBL] [Abstract][Full Text] [Related]
32. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study.
Mulder H; Cohen D; Scheffer H; Gispen-de Wied C; Arends J; Wilmink FW; Franke B; Egberts AC
J Clin Psychopharmacol; 2009 Feb; 29(1):16-20. PubMed ID: 19142101
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Houston JP; Kohler J; Bishop JR; Ellingrod VL; Ostbye KM; Zhao F; Conley RR; Poole Hoffmann V; Fijal BA
J Clin Psychiatry; 2012 Aug; 73(8):1077-86. PubMed ID: 22967772
[TBL] [Abstract][Full Text] [Related]
34. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia.
Eskelinen S; Sailas E; Joutsenniemi K; Holi M; Suvisaari J
Nord J Psychiatry; 2015 Jul; 69(5):339-45. PubMed ID: 25981178
[TBL] [Abstract][Full Text] [Related]
35. The discrete and combined effect of SREBP-2 and SCAP isoforms in the control of plasma lipids among familial hypercholesterolaemia patients.
Durst R; Jansen A; Erez G; Bravdo R; Butbul E; Ben Avi L; Shpitzen S; Lotan C; Leitersdorf E; Defesche J; Friedlander Y; Meiner V; Miserez AR
Atherosclerosis; 2006 Dec; 189(2):443-50. PubMed ID: 16466730
[TBL] [Abstract][Full Text] [Related]
36. Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients.
Tiwari AK; Zai CC; Meltzer HY; Lieberman JA; Müller DJ; Kennedy JL
Hum Psychopharmacol; 2010 Apr; 25(3):253-9. PubMed ID: 20373477
[TBL] [Abstract][Full Text] [Related]
37. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy?
Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM
Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650
[TBL] [Abstract][Full Text] [Related]
38. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
Ollendorf DA; Joyce AT; Rucker M
MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
[TBL] [Abstract][Full Text] [Related]
39. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia.
Mulder H; Franke B; van der-Beek van der AA; Arends J; Wilmink FW; Scheffer H; Egberts AC
J Clin Psychopharmacol; 2007 Aug; 27(4):338-43. PubMed ID: 17632216
[TBL] [Abstract][Full Text] [Related]
40. A pilot study investigating tumor necrosis factor-α as a potential intervening variable of atypical antipsychotic-associated metabolic syndrome in bipolar disorder.
Prossin AR; Zalcman SS; Evans SJ; McInnis MG; Ellingrod VL
Ther Drug Monit; 2013 Apr; 35(2):194-202. PubMed ID: 23503445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
